ANTIPLATELET THERAPY WITH CLOPIDOGREL TAKING INTO ACCOUNT CYP2C19 GENETIC POLYMORPHISMS IN PATIENTS WITH CORONARY HEART DISEASE AFTER CORONARY ARTERY STENTING

被引：1
|
作者：
Uzokov, J. [1 ]
Alyavi, B. [2 ]
Abdullaev, A. [1 ]
Muxitdinova, O. [2 ]
Ubaydullaeva, Z. [1 ]
机构：
[1] Republican Specialized Sci Pact Med Ctr Therapy &, Cardiol, Tashkent, Uzbekistan
[2] Tashkent Pediat Med Inst, Cardiol, Tashkent, Uzbekistan
来源：
ATHEROSCLEROSIS | 2021年 / 331卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P652
引用
收藏
页码：E265 / E265
页数：1
相关论文
共 50 条
  • [41] THE IMPACT OF CYP2C19*2 POLYMORPHISM ON ENDOTHELIAL FUNCTION AND ARTERIAL STIFFNESS IN PATIENTS WITH CORONARY ARTERY DISEASE RECEIVING CLOPIDOGREL
    Zaromitidou, Marina
    Siasos, Gerasimos
    Tousoulis, Dimitris
    Kioufis, Stamatios
    Oikonomou, Evangelos
    Maniatis, Konstantinos
    Miliou, Antigoni
    Kollia, Christina
    Michalea, Stavroula
    Zisimos, Konstantinos
    Kokkou, Eleni
    Papavassiliou, Athanasios G.
    Stefanadis, Christodoulos
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 59 (13) : E1409 - E1409
  • [42] Relationship between CYP2C19 Polymorphism and Clopidogrel Resistance in Patients with Coronary Heart Disease and Ischemic Stroke in China
    Chang, Rong
    Zhou, Wenqin
    Ye, Yi
    Zhang, Xiaofei
    Liu, Yanmin
    Wu, Jinchun
    GENETICS RESEARCH, 2022, 2022
  • [43] Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
    Chouchene, Saoussen
    Dabboubi, Rym
    Raddaoui, Haythem
    Abroug, Hela
    Ben Hamda, Khaldoun
    Fredj, Sondess Hadj
    Abderrazak, Fatma
    Gaaloul, Mayssa
    Rezek, Marwa
    Neffeti, Fadoua
    Hellara, Ilhem
    Sassi, Mouna
    Khefacha, Linda
    Sriha, Asma
    Nouira, Semir
    Najjar, Mohamed Fadhel
    Maatouk, Faouzi
    Messaoud, Taieb
    Hassine, Mohsen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (12) : 1567 - 1574
  • [44] Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?
    Saoussen Chouchene
    Rym Dabboubi
    Haythem Raddaoui
    Hela Abroug
    Khaldoun Ben Hamda
    Sondess Hadj Fredj
    Fatma Abderrazak
    Mayssa Gaaloul
    Marwa Rezek
    Fadoua Neffeti
    Ilhem Hellara
    Mouna Sassi
    Linda Khefacha
    Asma Sriha
    Semir Nouira
    Mohamed Fadhel Najjar
    Faouzi Maatouk
    Taieb Messaoud
    Mohsen Hassine
    European Journal of Clinical Pharmacology, 2018, 74 : 1567 - 1574
  • [45] Comparison of ticagrelor and clopidogrel in the treatment of patients with coronary heart disease carrying CYP2C19 loss of function allele
    Qian, Wenwen
    Chen, Liang
    Zhang, Lizhu
    Gao, Mingzhu
    Wang, Chunxia
    Qian, Xi
    Yang, Chengjian
    Lin, Yahui
    Han, Zhijun
    JOURNAL OF THORACIC DISEASE, 2022, : 2591 - 2601
  • [46] Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease
    Arya, V.
    Mahajan, P.
    Saraf, A.
    Mohanty, A.
    Sawhney, J. P. S.
    Bhargava, M.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, 37 (06) : 809 - 818
  • [47] Analysis of the Guiding Role of CYP2C19 Gene Combined With Platelet Function Detection in Antiplatelet Therapy in Patients With Complex Coronary Artery Disease After PCI
    Yu, Jiancai
    Liu, Yongxing
    Peng, Wanzhong
    Liu, Juan
    Li, Ya
    Liu, Junyan
    Jiang, Yang
    Liu, Demin
    Xu, Zesheng
    FRONTIERS IN SURGERY, 2022, 9
  • [48] Comparison of CYP2C19 Genotyping Methods in Cardiovascular Disease Patients Undergoing Percutaneous Coronary Intervention and Clopidogrel Therapy
    Han, J.
    Choi, J.
    Li, S.
    Goh, R.
    Kim, M.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2014, 16 (06): : 780 - 780
  • [49] Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
    Rajachandran, Manu
    Lange, Richard A.
    CURRENT CARDIOLOGY REPORTS, 2024, 26 (07) : 675 - 680
  • [50] INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
    Mirzaev, K. B.
    Kazakov, R. E.
    Smirnov, V. V.
    Andreev, D. A.
    Sychev, D. A.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2015, 11 (04) : 344 - 354
12345